Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia

Journal: Journal of Clinical Investigation

Published: 2020-08-13

DOI: 10.1172/jci139741

Affiliations: 19

Authors: 52

Go to article
Institutions Share
Mayo Clinic Department of Neuroscience, Florida Campus, United States of America (USA) 0.20
Center for Genomics of Neurodegenerative Disease Phatnani Lab (CGND), NYGC, United States of America (USA) 0.12
Mayo Clinic Graduate School of Biomedical Sciences, United States of America (USA) 0.11
UCL Department of Neuromuscular Diseases, United Kingdom (UK) 0.10
Mayo Clinic Department of Neurology, United States of America (USA) 0.10
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA) 0.06
Mayo Clinic Department of Cancer Biology, Florida Campus, United States of America (USA) 0.06
Mayo Clinic's Campus in Florida, United States of America (USA) 0.06
NIH National Institute of Neurological Disorders and Stroke (NINDS), United States of America (USA) 0.04
Oxford Nuffield Department of Clinical Neurosciences (NDCN), United Kingdom (UK) 0.04
UCL School of Life and Medical Sciences (SLMS), United Kingdom (UK) 0.04
UK DRI at The University of Edinburgh (UK DRI Edinburgh), United Kingdom (UK) 0.03
Euan MacDonald Centre for Motor Neurone Disease Research, The University of Edinburgh, United Kingdom (UK) 0.03
New York Genome Center (NYGC), United States of America (USA) 0.02
UCL Genetics Institute (UGI), United Kingdom (UK) 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER